95% effective volume of 0.33% ropivacaine for ultrason-guidedsupra-inguinal fascia iliaca block

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052214

Enrollment

Unknown

Registered

2021-10-22

Start date

2021-10-18

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:0.33% ropivacaine for ultrasound-guided supra-inguinal fascial iliac space block

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective total hip replacement under general anesthesia in the First Affiliated Hospital of Chongqing Medical University; 2. Aged 50-80 years, height 150-180 cm, weight 45-70 kg, American Society of Anesthesiologists (ASA) classification I-III.

Exclusion criteria

Exclusion criteria: 1. Those with obvious dysfunction of organs such as heart, brain, lung, liver and kidney; 2. Psychiatric patients, local skin infection at the puncture site, peripheral neuropathy, coagulation dysfunction, opioid abuse, chronic pain, patients who cannot cooperate to judge whether the analgesia is effective; 3. Patients taking adrenergic receptor blockers; 4. Patients with hypertension that cannot be controlled by drugs; 5. Patients with bradycardia; 6. Those who have unexpected situations such as drug allergy and massive bleeding during the operation; 7. Other patients who cannot tolerate this experiment.

Design outcomes

Primary

Measure	Time frame
pain assessment;	—

Countries

China

Contacts

Public ContactHe Kaihua

The First Affiliated Hospital of Chongqing Medical University

13908396469@163.com+86 13908396469

Outcome results